目的 通过奈达铂/紫杉烷与奥沙利铂/紫杉烷、卡铂/紫杉烷联合在妇科恶性肿瘤化疗方案的对比,了解奈达铂在妇科肿瘤联合化疗中的毒副反应.方法 选取2010年1月至2011年10月本院收治妇科恶性肿瘤患者133例,给予奈达铂/紫杉烷、奥沙利铂/紫杉烷、卡铂/紫杉烷联合化疗方案治疗,回顾性对比分析3组化疗方案引起的毒副反应.结果 奈达铂组和卡铂组在血红蛋白降低、白细胞降低及肝功损伤方面低于奥沙利铂组,但差异无统计学意义(P>0.05),中性粒细胞降低低于奥沙利铂组,差异有统计学意义(P＜0.05);奈达铂组血小板降低高于卡铂组(41.49%和34.35%),差异无统计学意义(P>0.05).卡铂组中1例患者因Ⅳ度骨髓抑制致感染未能控制而死亡;奈达铂组胃肠道反应低于奥沙利铂组和卡铂组,差异无统计学意义(P>0.05);奈达铂组中无过敏、肾功能损伤、发热发生,少部分轻度肝功能损伤和神经感觉异常.结论 奈达铂为新一代有效的广谱抗肿瘤药物,其联合化疗的毒副反应以骨髓抑制和胃肠道反应为主,和奥沙利铂、卡铂的比较差异无统计学意义,临床可根据患者的具体情况进行选择.%Objective Through comparing nedaplatin/taxane with oxaliplatin/taxane and carboplatin/taxane combination chemotherapy to understand the toxicity of nedaplatin combined chemotherapy regimen in patients with gynecological neoplasms.Methods From Jan.2010 to Oct.2011,133 patients with gynecological neoplasms were given chemotherapy regimen containing nedaplatin/ taxane or oxaliplatin/taxane or carboplatin/taxane.A comparative study of toxicity was made then among the three groups retrospectively.Results Nedaplatin group was lower than the oxaliplatin group in hemoglobin decrease,leukopenia,neutropenia with no statistical differences except for neutropenia,and also lower than carboplatin group with all no statistical differences(P>0.05).Nedaplatin group was higher than the oxaliplatin group in thrombopenia(41.49% ,29.52%) ,with statistical differences,and higher than carboplatin group(41.49%,34.35%) ,with no statistical differences(P>0.05).One patient was dead because of 4 grade rny-elosuppression induced infection.In nedaplatin group there was lower incidence in gastrointestinal toxicity than oxaliplatin group and carboplatin group with no statistical differences(P>0.05).There was no anaphylaxis,nephrotoxicity,fever appeared in nedaplatin group and a few patients had mild hepatic toxicity and neruotoxicity.Conclusion As a new generation anticancer drug,the main toxicity of nedaplatin was myelosuppression and gastrointestinal toxicity.There were no obvious differences in toxicity between nedaplatin and oxaliplatin^carboplatin in combined chemotherapy.Kither can be selected according to the patient s specific clinical situation.
展开▼
